Software Launches, Marketing Authorization Applications, and Market Movements - Analyst Notes on Hologic, Varian, Sirona, AcelRx and Smith & Nephew

NEW YORK, July 10, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Hologic Inc. (NASDAQ: HOLX), Varian Medical Systems Inc. (NYSE: VAR), Sirona Dental Systems Inc. (NASDAQ: SIRO), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) and Smith & Nephew plc (NYSE: SNN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4627-100free.

--
Hologic Inc. Analyst Notes
On July 7, 2014, Hologic, Inc.'s (Hologic) stock lost 2.13% to end the day at $25.46 compared to the previous day's closing price of $26.02. The Company's stock has gained 17.19% over the past three trading months compared to the NASDAQ Composite which grew 9.10% over the same trading period. The full analyst notes on Hologic are available to download free of charge at:

http://www.analystsreview.com/Jul-10-2014/HOLX/report.pdf

--
Varian Medical Systems Inc. Analyst Notes
On July 7, 2014, Varian Medical Systems, Inc.'s (Varian) stock increased slightly by 0.24% to end the day at $84.48 compared to the previous day's closing price of $84.28. The Company's stock has moved up by 0.63% in the last three trading days compared to the Dow Jones Industrial Average which rose 0.40% and Standard & Poor's 500 which increased 0.22% during the same trading period. The full analyst notes on Varian are available to download free of charge at:

http://www.analystsreview.com/Jul-10-2014/VAR/report.pdf

--
Sirona Dental Systems Inc. Analyst Notes
On July 1, 2014, Sirona Dental Systems Inc. (Sirona) announced the launch of CEREC 4.3 software, which offers users numerous innovations to improve the clinical quality of restorations and make workflow simpler and more efficient. The Company stated that the new software has the ability to record more details when creating digital impressions with the CEREC Omnicam, improving the accuracy of virtual models. Roddy MacLeod, Vice President CAD/CAM Systems at Sirona commented, "The great flexibility provided in the selection and processing of materials allows the dentist to provide his patient with a full range of solutions for a large number of indications, all in a single session. This makes CEREC particularly attractive, especially for newcomers." The software also checks whether the data from the scan is sufficiently networked and allows users to complete the imaging and design process more rapidly and simply. The full analyst notes on Sirona are available to download free of charge at:

http://www.analystsreview.com/Jul-10-2014/SIRO/report.pdf

--
AcelRx Pharmaceuticals, Inc. Analyst Notes
On July 7, 2014, AcelRx Pharmaceuticals, Inc. (AcelRx) together with Grunenthal Group announced that the latter has submitted a Marketing Authorization Application (MAA) to the European Medicines Authority for ZALVISO™ for the management of moderate to severe acute pain in adult patients in a medically supervised environment. AcelRx and Grunenthal entered into license and supply agreements for ZALVISOTM in the EU, Australia and certain other countries in December 2013. Under the terms of the license agreement, AcelRx will receive a cash payment of $5 million for the MAA submission, and is also eligible to receive $15 million milestone payment upon the approval of the MAA. Further, the Company stated that after the approval by EMA, it is eligible to receive approximately $200 million in additional milestone payments, based upon successful regulatory and product development efforts and net sales target achievements. The full analyst notes on AcelRx are available to download free of charge at:

http://www.analystsreview.com/Jul-10-2014/ACRX/report.pdf

--
Smith & Nephew plc Analyst Notes
On July 7, 2014, Smith & Nephew plc (Smith & Nephew) stock decreased slightly by 0.32% to end the day at $89.40. The Company's stock has gained 0.85% over the past five trading days, in line with the Standard & Poor's 500 which also rose 0.85% during the same trading period. The full analyst notes on Smith & Nephew are available to download free of charge at:

http://www.analystsreview.com/Jul-10-2014/SNN/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsReview.com

SOURCE Analysts Review